Cargando…
Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment
Rheumatoid arthritis (RA) patients are at high risk of cardiovascular (CV) events, and the chronic inflammatory state may generate quantitative and qualitative changes in lipoprotein fractions. The anti-IL-6 receptor tocilizumab (TCZ), even if effective in inflammation and joint damage prevention, d...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204176/ https://www.ncbi.nlm.nih.gov/pubmed/30405318 http://dx.doi.org/10.1155/2018/2453265 |
_version_ | 1783366002731384832 |
---|---|
author | Cacciapaglia, Fabio Anelli, Maria Grazia Rinaldi, Angela Fornaro, Marco Lopalco, Giuseppe Scioscia, Crescenzio Lapadula, Giovanni Iannone, Florenzo |
author_facet | Cacciapaglia, Fabio Anelli, Maria Grazia Rinaldi, Angela Fornaro, Marco Lopalco, Giuseppe Scioscia, Crescenzio Lapadula, Giovanni Iannone, Florenzo |
author_sort | Cacciapaglia, Fabio |
collection | PubMed |
description | Rheumatoid arthritis (RA) patients are at high risk of cardiovascular (CV) events, and the chronic inflammatory state may generate quantitative and qualitative changes in lipoprotein fractions. The anti-IL-6 receptor tocilizumab (TCZ), even if effective in inflammation and joint damage prevention, determined significant alterations to RA patients' lipid levels in randomized controlled trials, but real-world data are lacking. We evaluated the changes in lipid fraction levels and disease activity in a longitudinal cohort of RA patients on long-term treatment with tocilizumab (TCZ) in a community setting. We retrospectively selected 40 naïve-biologic RA patients on treatment with intravenous TCZ compared to 20 RA patients on methotrexate treatment as the control group. Total cholesterol (Tot-Chol), low-density lipoproteins (LDL), high-density lipoprotein (HDL), and triglyceride (TG) levels were measured at the baseline and at 12, 24, and 52 weeks thereafter. At the same points, 28-joint disease activity score (DAS28), clinical disease activity index (CDAI), and EULAR clinical responses were also assessed. During the first 24 weeks, we observed in TCZ-treated patients a progressive statistically significant (p < 0.001) increase in Tot-Chol, LDL, HDL, and TG, which returned close to the baseline at 52 weeks. But no changes in the lipid-related CV risk indices Tot-Chol/HDL and LDL/HDL ratios and the atherogenic index (log(10) TG/HDL) were detectable. Notably, we observed a statistically significant negative correlation between changes in lipid fractions and DAS28 or CDAI. The prolonged treatment with TCZ was associated to a transient increase in cholesterol's fractions during the first 6 months of treatment, with inverse correlation to disease activity, but with no impact on surrogate lipid indices of atherogenic risk. These findings may aid clinicians in interpreting the RA patient's lipid profile in daily clinical practice. |
format | Online Article Text |
id | pubmed-6204176 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-62041762018-11-07 Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment Cacciapaglia, Fabio Anelli, Maria Grazia Rinaldi, Angela Fornaro, Marco Lopalco, Giuseppe Scioscia, Crescenzio Lapadula, Giovanni Iannone, Florenzo Mediators Inflamm Research Article Rheumatoid arthritis (RA) patients are at high risk of cardiovascular (CV) events, and the chronic inflammatory state may generate quantitative and qualitative changes in lipoprotein fractions. The anti-IL-6 receptor tocilizumab (TCZ), even if effective in inflammation and joint damage prevention, determined significant alterations to RA patients' lipid levels in randomized controlled trials, but real-world data are lacking. We evaluated the changes in lipid fraction levels and disease activity in a longitudinal cohort of RA patients on long-term treatment with tocilizumab (TCZ) in a community setting. We retrospectively selected 40 naïve-biologic RA patients on treatment with intravenous TCZ compared to 20 RA patients on methotrexate treatment as the control group. Total cholesterol (Tot-Chol), low-density lipoproteins (LDL), high-density lipoprotein (HDL), and triglyceride (TG) levels were measured at the baseline and at 12, 24, and 52 weeks thereafter. At the same points, 28-joint disease activity score (DAS28), clinical disease activity index (CDAI), and EULAR clinical responses were also assessed. During the first 24 weeks, we observed in TCZ-treated patients a progressive statistically significant (p < 0.001) increase in Tot-Chol, LDL, HDL, and TG, which returned close to the baseline at 52 weeks. But no changes in the lipid-related CV risk indices Tot-Chol/HDL and LDL/HDL ratios and the atherogenic index (log(10) TG/HDL) were detectable. Notably, we observed a statistically significant negative correlation between changes in lipid fractions and DAS28 or CDAI. The prolonged treatment with TCZ was associated to a transient increase in cholesterol's fractions during the first 6 months of treatment, with inverse correlation to disease activity, but with no impact on surrogate lipid indices of atherogenic risk. These findings may aid clinicians in interpreting the RA patient's lipid profile in daily clinical practice. Hindawi 2018-10-14 /pmc/articles/PMC6204176/ /pubmed/30405318 http://dx.doi.org/10.1155/2018/2453265 Text en Copyright © 2018 Fabio Cacciapaglia et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Cacciapaglia, Fabio Anelli, Maria Grazia Rinaldi, Angela Fornaro, Marco Lopalco, Giuseppe Scioscia, Crescenzio Lapadula, Giovanni Iannone, Florenzo Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment |
title | Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment |
title_full | Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment |
title_fullStr | Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment |
title_full_unstemmed | Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment |
title_short | Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment |
title_sort | lipids and atherogenic indices fluctuation in rheumatoid arthritis patients on long-term tocilizumab treatment |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204176/ https://www.ncbi.nlm.nih.gov/pubmed/30405318 http://dx.doi.org/10.1155/2018/2453265 |
work_keys_str_mv | AT cacciapagliafabio lipidsandatherogenicindicesfluctuationinrheumatoidarthritispatientsonlongtermtocilizumabtreatment AT anellimariagrazia lipidsandatherogenicindicesfluctuationinrheumatoidarthritispatientsonlongtermtocilizumabtreatment AT rinaldiangela lipidsandatherogenicindicesfluctuationinrheumatoidarthritispatientsonlongtermtocilizumabtreatment AT fornaromarco lipidsandatherogenicindicesfluctuationinrheumatoidarthritispatientsonlongtermtocilizumabtreatment AT lopalcogiuseppe lipidsandatherogenicindicesfluctuationinrheumatoidarthritispatientsonlongtermtocilizumabtreatment AT sciosciacrescenzio lipidsandatherogenicindicesfluctuationinrheumatoidarthritispatientsonlongtermtocilizumabtreatment AT lapadulagiovanni lipidsandatherogenicindicesfluctuationinrheumatoidarthritispatientsonlongtermtocilizumabtreatment AT iannoneflorenzo lipidsandatherogenicindicesfluctuationinrheumatoidarthritispatientsonlongtermtocilizumabtreatment |